Order Before 3pm - Shipped Today

48 Hour UK Delivery

Pay by Bank or Crypto

Independently Lab-Tested

Appetite + Fat Loss Research Stack

£99.99

Purity: ≥ 99%

£99.99

Appetite + Fat Loss Research Stack

Name: Appetite + Fat Loss Research Stack
Brand: Pure Grade Labs
Price: 99.99 GBP
Availability: InStock

£99.99

Purity: ≥ 99%

£99.99

APPETITE & SATIETY - Triple hormone receptor agonism and neuroendocrine appetite regulation research

METABOLIC EFFICIENCY - AMPK activation, insulin sensitisation and WAT browning research

DIRECT LIPOLYSIS - GH receptor-mediated adipocyte triglyceride breakdown research

CARDIOMETABOLIC - Visceral fat, glucose, HbA1c and lipid parameter research

The Most Clinically Credentialed Fat Loss Stack in Peptide Research.

The Appetite+ Fat Loss Research Stack combines three compounds that address body fat reduction through entirely separate physiological systems. Retatrutide is a GLP-1/GIP/glucagon triple receptor agonist with Phase II human data published in the New England Journal of Medicine - 24.2% mean weight reduction at 48 weeks, no plateau observed at trial end. HGH Fragment 176-191 is the isolated lipolytic domain of human growth hormone, acting directly on GH receptors in adipocytes to stimulate fat breakdown without the systemic endocrine effects of full HGH. MOTS-C is a mitochondrial-derived peptide that improves metabolic efficiency at the cellular level via the AMPK pathway - independently of appetite, GH receptor signalling, or any endocrine mechanism.

Three distinct receptor systems. Three distinct sites of action. No pharmacokinetic competition. The combination is designed around the principle that addressing fat loss from multiple non-overlapping biological entry points produces a more comprehensive research picture than dose-escalating any single compound.

Retatrutide (LY3437943)

Triple agonist of GLP-1, GIP, and glucagon receptors. Developed by Eli Lilly. The first published triple hormone receptor agonist with Phase II RCT data. GLP-1 agonism drives appetite suppression and satiety via hypothalamic signalling. GIP agonism enhances insulin response and potentiates the GLP-1 signal. Glucagon agonism drives hepatic fat oxidation and thermogenesis via brown adipose tissue activation - the mechanism absent from semaglutide and tirzepatide that accounts for Retatrutide's superior weight loss in published comparisons. Phase III trials ongoing.

HGH Fragment 176-191

Amino acids 176-191 of the human growth hormone sequence - the C-terminal domain identified by Wu et al. (1994) as the minimum sequence for full lipolytic activity. Activates GH receptors on adipocytes, triggering triglyceride breakdown via JAK2/STAT5 and PI3K signalling. Does not elevate IGF-1, does not stimulate muscle growth, does not cause insulin resistance. Ng et al. (2000) confirmed equivalent fat reduction to full HGH in rodent obesity models without growth-promoting effects. Mechanism is direct adipocyte GH receptor agonism - entirely independent of appetite pathways or mitochondrial signalling.

MOTS-C

16-amino-acid peptide encoded by the 12S rRNA region of the mitochondrial genome - one of a small class of mitochondrial-derived peptides (MDPs). Under metabolic stress, translocates from mitochondria to the nucleus to regulate nuclear gene expression via the Folate-AICAR-AMPK pathway. Improves insulin sensitivity, increases glucose uptake in skeletal muscle, promotes white-to-brown adipose tissue conversion. Plasma levels are 11-21% lower in middle-aged versus young adults and rise 1.5-fold in response to exercise. Acts as an endogenous exercise-mimetic. Mechanism is cellular and mitochondrial - no interaction with GLP-1, GIP, glucagon, or GH receptor systems.

Retatrutide (LY3437943) - Modified GLP-1/GIP/Glucagon Triple Agonist: C20 fatty diacid-modified peptide (proprietary Eli Lilly sequence) - MW: ~4,817 g/mol - CAS: 2381272-06-4

HGH Fragment 176-191 Sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe-OH - MW: 1,815.1 g/mol - CAS: 66004-57-7

MOTS-C Sequence (Mitochondrial-Encoded, 16 AA): Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg - MW: 2,174.6 g/mol - CAS: 1627580-64-6

Retatrutide Target: GLP-1R / GIPR / GCG-R

Frag 176-191 Target: GH Receptor (Adipocyte)

MOTS-C Target: AMPK / Mitochondria

Receptor Overlap: None

2023 | New England Journal of Medicine | Phase II RCT (n=338)

Retatrutide achieves 24.2% mean weight reduction at 48 weeks with no plateau - Phase II obesity trial

Jastreboff et al. conducted a multicenter, double-blind, randomised, placebo-controlled Phase II trial in 338 adults with obesity (BMI 30+) without type 2 diabetes. Participants received once-weekly subcutaneous retatrutide at 1mg, 4mg, 8mg, or 12mg, or placebo for 48 weeks. At 48 weeks, the 12mg group showed a mean weight reduction of 24.2% versus -2.1% with placebo. At the 8mg dose: 100% of participants achieved at least 5% weight loss, 91% achieved 10%, and 75% achieved 15% - rates that exceeded tirzepatide's published Phase III data at comparable timepoints. Weight loss was still progressing at 48 weeks with no plateau detected, suggesting continued efficacy beyond the study window. Cardiometabolic parameters improved across the board: waist circumference, blood pressure, fasting glucose, HbA1c, and LDL cholesterol (the latter via glucagon-mediated PCSK9 degradation). 72% of subjects with baseline prediabetes reverted to normoglycemia. The safety profile was consistent with GLP-1 receptor agonists, with transient, dose-dependent GI events during escalation being the primary adverse effects.

Jastreboff AM, et al. N Engl J Med. 2023;389(6):514-526. PubMed →

2023 | The Lancet | Phase II RCT / Type 2 Diabetes (n=281)

Retatrutide reduces bodyweight by 16.9% and HbA1c by 2.2% in type 2 diabetes - superior to dulaglutide at all endpoints

Rosenstock et al. conducted a Phase II trial in 281 adults with type 2 diabetes comparing retatrutide at multiple doses versus placebo and versus dulaglutide 1.5mg (a standard GLP-1 agonist). At 36 weeks, the 12mg retatrutide group achieved mean weight reduction of 16.9% versus 3% with placebo and 2% with dulaglutide. HbA1c decreased by 2.2%, with 82% of participants reaching the euglycaemic target of HbA1c at or below 6.5%. Retatrutide was statistically superior to dulaglutide on both weight and glycaemic endpoints (p<0.0001). The authors attributed the advantages over dulaglutide - and over dual GLP-1/GIP agonists - specifically to the addition of glucagon receptor agonism, which drives hepatic fat oxidation and energy expenditure increases not achievable through GLP-1/GIP agonism alone. These data informed dose selection for the Phase III TRIUMPH programme.

Rosenstock J, et al. Lancet. 2023;402(10401):529-544. PubMed →

2015 | Cell Metabolism | Animal Study + Human Observation

MOTS-C prevents obesity and insulin resistance via AMPK - confirmed as exercise-induced mitochondrial signal in humans

Lee et al. characterised MOTS-C's metabolic function in its foundational study. In high-fat diet mouse models, MOTS-C prevented diet-induced obesity, reduced adiposity, and restored insulin sensitivity without caloric restriction. The mechanism was identified as the Folate-AICAR-AMPK pathway: MOTS-C drives AICAR accumulation, activating AMPK and mimicking the cellular effects of aerobic exercise in skeletal muscle. In adipose tissue, MOTS-C promoted browning of white adipose tissue - increasing thermogenic capacity through upregulation of uncoupling protein 1 (UCP1). Human data confirmed that MOTS-C rises 1.5-fold in circulation following exercise, establishing it as an endogenous exercise-response signal. The authors characterised MOTS-C as an "exercise mimetic" - a compound that activates metabolic pathways of physical activity through a mitochondrial-nuclear signalling axis entirely independent of any endocrine or GH receptor mechanism.

Lee C, et al. Cell Metab. 2015;21(3):443-454. PubMed →

2000 | Endocrinology | Animal Study

HGH Fragment 176-191 achieves equivalent fat reduction to full HGH in obese mice without growth-promoting effects

Ng et al. compared HGH Fragment 176-191 against full recombinant HGH in obese rodent models at matched dosing. Fragment 176-191 reduced body fat to the same degree as full HGH and produced equivalent stimulation of lipolysis in isolated adipocytes. Critically, the fragment produced none of the systemic endocrine effects associated with full HGH: no changes in linear growth, no IGF-1 elevation, no lean mass increase, and no insulin resistance. The lipolytic effect was confirmed as GH receptor-mediated - confirming direct adipocyte engagement rather than action through an off-target or secondary receptor. The study established that the lipolytic properties of HGH are structurally separable from its anabolic and diabetogenic properties, and that Fragment 176-191 provides a research tool for studying fat metabolism specifically, without the confounding systemic hormonal changes that full HGH produces. This independence from any appetite or AMPK pathway is what makes it non-redundant with Retatrutide and MOTS-C in a multi-compound protocol.

Ng FM, et al. Endocrinology. 2000;141(11):4000-4008. PubMed →

Every Appetite+ Fat Loss Research Stack ships with a batch-specific Certificate of Analysis from an independent third-party analytical laboratory, covering all three compounds. The COA confirms identity, purity by HPLC, and absence of contaminants for your specific batch.

All three compounds are supplied as lyophilised (freeze-dried) solids requiring reconstitution with bacteriostatic water before use in research protocols. BAC water is available separately. Storage specifications apply to all three vials.

Temperature: -20°C Long-term storage. For short-term use (up to 4 weeks), 2-8°C is acceptable.

Light Sensitivity: Light-Sensitive. Store in original opaque vial. Avoid direct UV or prolonged exposure to light.

Shelf Life: 24 Months. Lyophilized, sealed, stored at -20°C. Batch expiry printed on vial label.

Allow sealed vials to reach room temperature before opening to minimise moisture introduction. Bacteriostatic water is supplied ready to use - no preparation required.
Use the included bacteriostatic water as reconstitution solvent. Add solvent slowly down the inside wall of the vial - do not inject directly onto the lyophilised cake.
Gently swirl each vial until fully dissolved. Do not vortex or shake vigorously. Both compounds dissolve readily in BAC water.
Once reconstituted, store at 2-8°C. Use within 28 days. Do not freeze reconstituted solution.
Discard if solution appears cloudy, discoloured, or contains particulate matter.

Retatrutide, HGH Fragment 176-191, and MOTS-C supplied by Pure Grade Labs are intended exclusively for in vitro research and laboratory use. These products are not approved for human or veterinary use by any regulatory authority, including the FDA, MHRA, TGA, or EMA.

Retatrutide (LY3437943) is an investigational compound in active Phase III clinical development by Eli Lilly. It is not approved for human use in any jurisdiction. This supply is for research use only and is not affiliated with Eli Lilly or its clinical programme.
Pure Grade Labs makes no claims regarding therapeutic or clinical efficacy in humans beyond what is described in the cited research literature.
These products must not be administered to humans or animals outside of a licensed research context.
Retatrutide in particular has significant cardiometabolic activity and should only be studied within properly supervised, protocol-driven research settings.
All three compounds are prohibited in sport by WADA under applicable categories. Athletes subject to drug testing must not order or use these products.
Purchasers are solely responsible for compliance with all applicable laws and regulations in their jurisdiction.

All research summaries and study citations on this page are provided for informational context only and do not constitute medical advice, endorsement of any treatment, or recommendation for human use.